On 21 May 2025, Biocon Biologics announced that Yoshindo, its commercial partner, has launched Ustekinumab BS Subcutaneous Injection in Japan for treatment of psoriasis vulgaris and psoriatic arthritis.
The launch follows the January 2025 approval of the subcutaneous ustekinumab (Bmab 1200), biosimilar to J&J/Janssen’s Stelara®, by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
Biocon signed a patent settlement and licence agreement with J&J/Janssen in 2024, which resolved patent disputes between the parties, and enables Biocon to commercialise its ustekinumab biosimilar (Bmab 1200/Yesintek®) in Europe, the United Kingdom, Canada and Japan.
Biocon launched Yesintek™ in the US in February 2025 following its approval in early December 2024 for multiple indications, including plaque psoriasis, active psoriatic arthritis, Crohn’s disease and ulcerative colitis. Yesintek® was approved in Europe in February 2025.